Coya Therapeutics, Inc. Asset Profile

= Subscriber Access Only

You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.

Year established

2020

Location

Houston TX US

Primary Industry

Biotechnology

About

Founded in 2020 and based in Texas, US, Coya Therapeutics, Inc. is a clinical-stage biotechnology company developing approaches to utilizing adaptive regulatory T cells (Tregs) to target disease. The company was founded by its CEO, Howard Berman. In December 2023, Coya Therapeutics, Inc. raised USD 5.61 million in PIPE funding from Greenlight Capital. The company is listed on Nasdaq under the ticker COYA. The company specializes in the development of therapies aimed at enhancing regulatory T cell (Treg) function. These therapies target a range of conditions, including neurodegenerative, autoimmune, and metabolic diseases. Coya’s approach focuses on multiple Treg therapeutic modalities, leveraging data, particularly in Amyotrophic Lateral Sclerosis (ALS) and Alzheimer’s disease. Coya Therapeutics' product pipeline includes COYA 302 and COYA 301, which are Treg-enhancing biologics intended to bolster the body's regulatory T cells to combat disease; COYA 201, which comprises allogeneic Treg-derived exosomes, which are small vesicles that carry therapeutic benefits for neurodegenerative and autoimmune conditions; and COYA 101, which is an autologous Treg cell therapy where a patient's own cells are used to enhance their immune system's regulatory capabilities.

Current Investors

Greenlight Capital, Allele Capital Partners

Request a demo to show more

Primary Industry

Biotechnology

Sub Industries

Molecular Science, Genetics & Gene Therapy, Biopharmaceuticals

Website

www.coyatherapeutics.com/

Company Stage

Mature

Total Amount Raised

Subscriber access only

Deals

Deals Type
PIPE

Deal Status	Target (s)	Deal Date	Investor(s)	Seller(s)	Deal size (Mn)	Enterprise value (Mn)	Post-money valuation (Mn)	EBITDA multiple (x)	Revenue multiple (x)	Lead partner (s)
Completed	Coya Therapeutics, Inc.	12 Dec 2023

Displaying 1-1 of 1

Time to go Pro

Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.